PGC-1α activation as a therapeutic approach in mitochondrial disease

87Citations
Citations of this article
91Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Mitochondria play a central role in cellular homeostasis. Hence, mitochondrial dysfunction resulting in impaired ATP supply is detrimental to cell viability and causes severe and often fatal disorders. Current treatment of these mitochondrial disorders is limited and mostly addresses the symptoms, but not the deficiency itself. Recent work in cell and animal models of mitochondrial disease shows that increased mitochondrial biogenesis can boost residual OXPHOS capacity and thereby prevent the bioenergetic crisis. In animal models, this strategy results in increased health and lifespan. Here, I review which mitochondrial processes are affected in known mitochondrial disorders and discuss why PGC-1α mediated mitochondrial biogenesis offers a promising venue for treatment of mitochondrial disorders. α 2009 IUBMB.

Cite

CITATION STYLE

APA

Wenz, T. (2009). PGC-1α activation as a therapeutic approach in mitochondrial disease. IUBMB Life. https://doi.org/10.1002/iub.261

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free